Evidence map›Paper›PMID 32594284›Full record

ArticleJournal of assisted reproduction and genetics2020

Installing oncofertility programs for common cancers in limited resource settings (Repro-Can-OPEN Study): An extrapolation during the global crisis of Coronavirus (COVID-19) pandemic.

M Salama, L Ataman-Millhouse, M Braham, K Berjeb, M Khrouf, J K Rodrigues, F M Reis, T Cury- Silva, F Sánchez, S Romero and 41 more

Abstract read
In one paragraph

Article in Journal of assisted reproduction and genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. A synopsis of global frontiers in fertility preservation.Journal of assisted reproduction and genetics · 2022
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

51 authors.

M SalamaOncofertility Consortium, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. eaims_gm@yahoo.com.ORCID http://orcid.org/0000-0002-0282-8018
L Ataman-MillhouseOncofertility Consortium, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
M BrahamAziza Othmana Hospital of Tunis, Tunis, Tunisia.
K BerjebAziza Othmana Hospital of Tunis, Tunis, Tunisia.
M KhroufFERTILLA, Clinique la Rose, Tunis, Tunisia.
J K RodriguesUniversidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
F M ReisUniversidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
T Cury- SilvaUniversidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
F SánchezLaboratorio de Biología Reproductiva y Preservación de la Fertilidad, Laboratorios de Investigación y Desarrollo, Universidad Peruana Cayetano Heredia, Lima, Peru.
S RomeroLaboratorio de Biología Reproductiva y Preservación de la Fertilidad, Laboratorios de Investigación y Desarrollo, Universidad Peruana Cayetano Heredia, Lima, Peru.
J SmitzLaboratorio de Biología Reproductiva y Preservación de la Fertilidad, Laboratorios de Investigación y Desarrollo, Universidad Peruana Cayetano Heredia, Lima, Peru.
L VásquezUnidad de Oncología Pediátrica, Hospital Edgardo Rebagliati Martins, Lima, Peru.
M VegaPanama Fertility, Sistema Nacional de Investigadores, Panama City, Panama.
F SobralPregna Medicina Reproductiva, Buenos Aires, Argentina.
G TerradoPregna Medicina Reproductiva, Buenos Aires, Argentina.
M G LombardiPregna Medicina Reproductiva, Buenos Aires, Argentina.
A ScarellaCentro de Reproduccion Humana, Facultad de Medicina, Universidad de Valparaiso, Valparaiso, Chile.
M T BourlonInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
H Verduzco-AguirreInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
A M SánchezInstituto Nacional de Perinatología Isidro Espinoza de los Reyes, Mexico City, Mexico.
S K AdigaFertility Preservation Centre, Department of Clinical Embryology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India.
P TholetiFertility Preservation Centre, Department of Clinical Embryology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India.
K S UdupaDepartment of Medical Oncology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India.
N MahajanMother and Child Hospital, New Delhi, India.
M PatilDr. Patil's Fertility and Endoscopy Clinic, Bangalore, India.
R DalviHospital Institute of Medical Sciences & SRCC children's Hospital, Mumbai, India.
C VenterVitalab Fertility Centre, Johannesburg, South Africa.
G DemetriouDepartment Medical Oncology, University of Witwatersrand, Johannesburg, South Africa.
J GeelCharlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.
R QuintanaProcrearte, Buenos Aires, Argentina.
G RodriguezProcrearte, Buenos Aires, Argentina.
T QuintanaProcrearte, Buenos Aires, Argentina.
L VialeProcrearte, Buenos Aires, Argentina.
M FragugliaProcrearte, Buenos Aires, Argentina.
M CoiriniHospital de Niños Victor J. Vilela. Rosario, Santa Fe, Argentina.
Y A Remolina-BonillaInstituto Nacional de Cancerología, Bogota, Colombia.
J A R NogueraInstituto Nacional de Cancerología, Bogota, Colombia.
J C VelásquezInstituto Nacional de Cancerología, Bogota, Colombia.
A SuarezInstituto Nacional de Cancerología, Bogota, Colombia.
G D ArangoFERTIVIDA Fertility Center, Bogota, Colombia.
J I D PinedaInstituto Guatemalteco de Seguridad Social (IGSS), Guatemala City, Guatemala.
M D C AldecoaInstituto Guatemalteco de Seguridad Social (IGSS), Guatemala City, Guatemala.
M JavedThuriah Medical Center, Riyadh, Kingdom of Saudi Arabia.
H Al SufyanThuriah Medical Center, Riyadh, Kingdom of Saudi Arabia.
N DanielsThe Oncology and Fertility Centres of Ekocorp Plc, Eko Hospitals, Lagos, Nigeria.
B C OranyeThe Oncology and Fertility Centres of Ekocorp Plc, Eko Hospitals, Lagos, Nigeria.
A A OgunmokunThe Oncology and Fertility Centres of Ekocorp Plc, Eko Hospitals, Lagos, Nigeria.
K I OnwuzurigboKingswill Specialist Hospital, Lagos, Nigeria.
C J OkerekeKingswill Specialist Hospital, Lagos, Nigeria.
T C WhesuKingswill Specialist Hospital, Lagos, Nigeria.
T K WoodruffOncofertility Consortium, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. tkw@northwestern.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe state of limited resource settings that Coronavirus (COVID-19) pandemic has created globally should be taken seriously into account especially in healthcare sector. In oncofertility, patients should receive their fertility preservation treatments urgently even in limited resource settings before initiation of anticancer therapy. Therefore, it is very crucial to learn more about oncofertility practice in limited resource settings such as in developing countries that suffer often from shortage of healthcare services provided to young patients with cancer.

methodsAs an extrapolation during the global crisis of COVID-19 pandemic, we surveyed oncofertility centers from 14 developing countries (Egypt, Tunisia, Brazil, Peru, Panama, Mexico, Colombia, Guatemala, Argentina, Chile, Nigeria, South Africa, Saudi Arabia, and India). Survey questionnaire included questions on the availability and degree of utilization of fertility preservation options in case of childhood cancer, breast cancer, and blood cancer.

resultsAll surveyed centers responded to all questions. Responses and their calculated oncofertility scores showed different domestic standards for oncofertility practice in case of childhood cancer, breast cancer, and blood cancer in the developing countries under limited resource settings.

conclusionsMedical practice in limited resource settings has become a critical topic especially after the global crisis of COVID-19 pandemic. Understanding the resources necessary to provide oncofertility treatments is important until the current COVID-19 pandemic resolves. Lessons learned will be valuable to future potential worldwide disruptions due to infectious diseases or other global crises.

Indexed as

BetacoronavirusCoronavirus InfectionsCOVID-19Delivery of Health CareDeveloping CountriesFemaleFertility PreservationHumansNeoplasmsPandemicsPneumonia, ViralSARS-CoV-2Surveys and QuestionnairescancerCOVID-19limited resource settingsoncofertilitypandemic

Identifiers

PMID32594284
PMCPMC7320246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.